Navigation Links
SuperGen Reports 2008 First Quarter Financial Results
Date:4/28/2008

ale of products resulting from the sale of the Company's North American rights for Nipent and Surface Safe(R) to Mayne Pharma. The gain on sale of products for the 2008 first quarter of $1 million represents receipt of an indemnification holdback paid by Mayne Pharma to the Company in February 2008 after expiration of a contractual holding period. There was no similar gain in the same prior year period. Stock-based compensation expense, which is included in operating expenses, was $747,000 for the 2008 first quarter, compared with $1.2 million for the same prior year period.

The Company reported a net loss for the 2008 first quarter of $1.1 million, or $0.02 per share, compared with a net loss of $3.3 million, or $0.06 per share, for the same prior year period.

As of March 31, 2008, the Company had approximately $90.8 million in current and non-current unrestricted cash, cash equivalents and marketable securities.

"We are pleased to end the 2008 first quarter with nearly the same amount of cash, cash equivalents and marketable securities that we had at the end of 2007, given that we have considerably advanced the development of MP-470, our clinical-stage tyrosine kinase (TK) inhibitor and Rad51 suppressor, and SGI-1776 and S-110, two of our pre-clinical stage compounds," said Dr. James Manuso, SuperGen's President and Chief Executive Officer. "We are on schedule to begin Phase 1 clinical trials with SGI-1776 before year-end. Dacogen royalty revenues have continued to largely offset our operating expenses and productivity has been further enhanced across the discovery and development functions."

2008 Revised Financial Guidance

The Company expects to report royalty revenue for 2008 in a range from $32 million to $35 million. The Company's royalty revenue is initially based on the annual end user guidance of approximately $157 million for 2008 provided by Eisai Co., Ltd. in their quarterly conference call in early February 2008. The C
'/>"/>

SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... iLab Solutions announced the results of its ... on core facility operations, growth and utilization as well ... In its 4th year running, a number of long-term ... decrease in the percentage of revenue that comes from ... constraints of this trend. When asked, “What are your ...
(Date:9/30/2014)... LONDON , Sept. 30, 2014 ... analyze global next-generation (NGS) sequencing trends and use. ... technology use is expected to increase within the ... are the top criteria for purchasing sequencing instruments. ... technologies. The popularity of RNA-Seq continues to surge, ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 The custom ... ISPE Boston Product Show 2014. The Boston Area Chapter ... the 23rd annual, day-long event for Wed., Oct. 1 ... promises to be the largest in ISPE Boston’s long ... upward of 3,000 attendees expected. , HOLLOWAY AMERICA ...
(Date:9/30/2014)... Lyme Research Alliance (LRA), ... research at universities, today announced the awarding of seven ... treatment and cure for Lyme and other tick-borne diseases. ... applications in its history—over 20 grant proposals—a 100 percent ... pleased to receive so many solid applications from talented ...
Breaking Biology Technology:iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3Global Next-generation Sequencing Trends 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4
... Calif., Sept. 29, 2011 Ambry Genetics today ... provide CLIA-approved exome services for applications in clinical ... geneticists and medical directors, these results will allow ... have eluded traditional diagnostic approaches. ...
... 29, 2011 Dr. Barrett Bready, CEO of NABsys, ... Year. Dr. Bready will be honored at a ceremony ... presented by the Providence Business News in partnership with ... Bryant University, Cox Business, Edwards Angell Palmer & Dodge, ...
... system, you probably think about it fighting off a cold. ... immune cells in your brain may contribute to how you ... 10,000 years of using alcohol, and several decades of investigation ... our brain, we are still trying to figure out exactly ...
Cached Biology Technology:Ambry Genetics First to Offer Exome Sequencing Service for Clinical Diagnostics. 2NABsys CEO Barrett Bready Named Rhode Island Innovator of the Year 2Alcohol-related behavior changes -- blame your immune system 2
(Date:9/29/2014)... from the skeleton of a man who lived 2,330 years ... ourselves as humans? A great deal when his DNA profile ... terms found to-date in a region where modern humans ... , The man,s maternal DNA, or ,mitochondrial DNA, was sequenced ... Mitochondrial DNA provided the first evidence that we all come ...
(Date:9/29/2014)... -- NXT-ID, Inc. (Nasdaq: NXTD and ... focused on the growing mobile commerce market, today announced ... the Company,s Vice-President and Chief Financial Officer effective immediately. ... Financial Officer. Mr. Pereira will continue to serve as ... Mr. Miceli, age 56, has extensive hands ...
(Date:9/29/2014)... were able to safely tolerate treatment with cells cultured ... today in the journal Multiple Sclerosis and Related ... its kind, was conducted by researchers at Mount Sinai, ... at several other institutions. , While designed to ... data also suggested that a preparation of cultured cells ...
Breaking Biology News(10 mins):Ancient human genome from southern Africa throws light on our origins 2Ancient human genome from southern Africa throws light on our origins 3NXT-ID, Inc. Names Vice-President and Chief Financial Officer 2NXT-ID, Inc. Names Vice-President and Chief Financial Officer 3Cells from placentas safe for patients with multiple sclerosis 2
... A team led by the University of Colorado Boulder has been ... Energy to research modifying E. coli to produce biofuels ... take what we have worked on for the past decade to ... CU-Boulder,s Renewable and Sustainable Energy Institute, or RASEI. "In this project, ...
... Ian Bell, PhD, the Louis Block Distinguished Service Professor ... the Kovler Diabetes Center at the University of Chicago, ... 2012 for his pioneering work in understanding the role ... The prize, the world,s largest award for ...
... scientists produce better climate-resistant corn and other food production plants ... what we eat. Kansas State University geneticists and colleagues ... and prioritize the genes in humans, it improved the likelihood ... control quantitate traits in plants, such as how the plants ...
Cached Biology News:CU-led team receives $9.2 million DOE grant to engineer E. coli into biofuels 2University of Chicago's Graeme Bell receives international diabetes prize 2University of Chicago's Graeme Bell receives international diabetes prize 3Study finds prioritizing rather than canvassing entire plant genome may lead to improved crops 2Study finds prioritizing rather than canvassing entire plant genome may lead to improved crops 3
High affinity antibody reacting with S-100 ab heterodimer. Could be used for Western blotting application and immunoassay....
... Ingredients (g/L):,Tryptone, 10 ,Yeast extract, ... ,S-Gal, 0.3 ,Ferric ammonium citrate, 0.5 ... patented, water soluble, autoclavable chromogenic substrate ... S-Gal by -galactosidase generates a black ...
S-100 alpha/beta chain (8B10)...
SCCRO (S-17)...
Biology Products: